drugset / Trial / NCT03656562
Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of treatment with either VAY736 (ianalumab) or CFZ533 (iscalimab) in patients with systemic lupus erythematosus (SLE) to enable further development of these compounds as treatment in this disease population
Timeline
- Start
- 2018-12-19
- Primary completion
- 2022-07-27
- Completion
- 2025-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ianalumab | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | iscalimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | iscalimab | Monoclonal antibody | 13 mg/kg | Intravenous |